RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo2556.2015
T1  - Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
A1  - Y. Li
A1  - X. Wang
A1  - J. Li
A1  - W. Ding
K1  - Cervical cancer; Neoadjuvant chemotherapy; Liposomal paclitaxel; Locally advanced.
YR  - 2015
SP  - 54
AB  - <p><i>Objectives: </i>To investigate the efficacy and toxicities of combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy (NACT) in locally advanced cervical cancer. <i>Materials and Methods: </i>The authors retrospectively reviewed the clinical records of patients with cervical cancer who received NACT with liposomal paclitaxel and cisplatin at Sun Yat-sen University Cancer Center from April 1, 2008 to December 31, 2012. Liposomal paclitaxel and cisplatin was administrated intravenously at a dose of 175 mg/m2 and 75 mg/m2, respectively. <i>Results: </i>The total response rate was 86.1% (62/72) including a complete response and partial response rate of 27.8 % (20/72) and 58.3% (42/72), respectively. Stable disease was observed in 12.5 % (9/72) of patients and progressive disease in 1.4 % (1/72). Hematological toxicities were the major dose-limiting toxicities. Grade 3/4 neutropenia and anemia developed in 18.1% (13/72) and 6.9% (5/72) of patients, respectively. Peripheral neuropathy occurred in 6.9% (5/72) of patients (all grade 1). <i>Conclusion:</i> the study findings support further evaluation of liposomal paclitaxel with cisplatin as an additional chemotherapy regimen which may be efficacious and tolerable in the NACT of cervical cancer.</p>